XFOR X4 Pharmaceuticals (XFOR) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001501697
C-suite buying · 1Form 144 · 3
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
57
13F, latest reported quarter
What the filings say about XFOR
Insiders, 180 days
-$451.0K net sold
1 buyer · 3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$361.7K
3 notices
X4 Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, X4 Pharmaceuticals, Inc insiders sold a net $451.0K of stock across 82 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Aug 12, 2026.
- The trade is 1.4% of the 333,251 shares held after it.
- No other insider bought within 30 days.
- 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Chairman Craig Adam R bought about $11.9K of XFOR on Oct 16, 2026; 57 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 30, 2026.
- The trade is 7.5% of the 155,983 shares held after it.
- No other insider sold within 30 days.
- 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer KIRSKE DAVID sold about $33.7K of XFOR on Oct 1, 2026; 57 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Oct 23, 2025.
- The trade is 14.4% of the 328,651 shares held after it.
- 1 other insider sold within 30 days.
- 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Chairman Craig Adam R sold about $210.8K of XFOR on Aug 12, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 57 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 9.3% of the 265,305 shares held after it.
- 1 other insider sold within 30 days.
- 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President Volpone John sold about $109.2K of XFOR on Aug 12, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 57 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 12, 2026.
- The trade is 5.1% of the 167,750 shares held after it.
- No other insider sold within 30 days.
- 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer KIRSKE DAVID sold about $36.4K of XFOR on Jun 30, 2026; 57 funds added in the latest 13F quarter.82 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$451.0K over 180 days
-$341.8K over 90 days
below 55% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
57 funds bought in last quarter
more than 50% of Pharma & Biotech
Revenue
+1273.2% year over year
more than 97% of Pharma & Biotech
Margin
-225.6% net margin
below 67% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
13.3% of the float short (float per yahoo 2026-10-26) · 6.0 days to cover · settled 2026-09-30
more than 62% of Pharma & Biotech
What changed in the last 30 days
Oct 19Executive Chairman Craig Adam R bought $11.9K (Oct 16)
Oct 5Chief Financial Officer KIRSKE DAVID sold $33.7K (Oct 1)
Oct 1Officer David Kirske filed to sell $33.7K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch XFOR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+4.8%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns XFOR: institutional holders (13F)
13F holdings, latest reported quarter
9,461,279 sh
$44.2M
8,321,657 sh
$38.9M
7,967,454 sh
$37.2M
7,933,491 sh
$37.0M
7,445,680 sh
$34.8M
Congress trades in XFOR
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
XFOR planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
David Kirske
Filed 2026-10-01
$33.7K
Adam Craig
Filed 2026-08-13
$216.1K
John Volpone
Filed 2026-08-13
$111.9K
XFOR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Inception Portfolio
$10.8M position · as of 2026-06-30
3.8%
EQ/Morgan Stanley Small Cap Growth Portfolio
$8.5M position · as of 2026-06-30
1.8%
Fidelity Advisor Biotechnology Fund
$5.3M position · as of 2026-07-31
0.2%
Fidelity Small Cap Stock K6 Fund
$33.1K position · as of 2026-07-31
0.2%
Fidelity Small Cap Growth Fund
$13.5M position · as of 2026-07-31
0.2%
Fidelity Small Cap Stock Fund
$2.0M position · as of 2026-07-31
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 1
0 active
1
Phase 2
0 active
2
Phase 3
1 active
2
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Dr. Ragan
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$3.9M
$3.3M
$1.9M
-85%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $451.0K sold by insiders over 180 days, 57 funds added last quarter, $361.7K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
XFOR financials
Revenue growth
+1273.2%
XBRL, annual
Net margin
-225.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$15.8M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM XFOR
| FY Dec 2025 | $35.1M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | $0 |
| FY Dec 2021 | $0 |
| Jun 2026 | $8.8M |
| Mar 2026 | $2.7M |
| Dec 2025 | $2.6M |
| Sep 2025 | $1.8M |
| Jun 2025 | $2.0M |
| Mar 2025 | $28.8M |
| Dec 2024 | $1.5M |
| Sep 2024 | $560.0K |
At each fiscal year end
Single quarter
Net margin, TTM
-568.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM XFOR
| FY Dec 2025 | -225.6% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -183.5% |
| Mar 2026 | -747.5% |
| Dec 2025 | -931.7% |
| Sep 2025 | -1,689% |
| Jun 2025 | -1,305% |
| Mar 2025 | +1.0% |
| Dec 2024 | -2,696% |
| Sep 2024 | -6,553% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$83.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM XFOR
| FY Dec 2025 | -$85.6M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -$77.2M |
| FY Dec 2021 | -$71.5M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$15.5M |
| Sep 2025 | -$27.8M |
| Jun 2025 | -$29.9M |
| Mar 2025 | -$12.4M |
| Dec 2024 | -$33.0M |
| Sep 2024 | -$34.1M |
At each fiscal year end
Single quarter
Debt to equity
0.48x
LongTermDebt as filed 2026-06-30 (includes the current portion); equity 2026-06-30
Debt to equity XFOR
| FY Dec 2025 | 0.40x |
| FY Dec 2024 | 3.39x |
| FY Dec 2023 | 1.07x |
| FY Dec 2022 | 0.45x |
| FY Dec 2021 | 0.53x |
| Jun 2026 | 0.48x |
| Mar 2026 | 0.45x |
| Dec 2025 | 0.40x |
| Sep 2025 | 1.22x |
| Jun 2025 | 18.89x |
| Mar 2025 | 3.27x |
| Dec 2024 | 3.39x |
| Sep 2024 | 1.26x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.12x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
Cash flow to debt XFOR
| FY Dec 2025 | -1.14x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -2.29x |
| FY Dec 2021 | -2.09x |
| Jun 2026 | -1.12x |
| Mar 2026 | -1.24x |
| Dec 2025 | -1.14x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-113.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity XFOR
| FY Dec 2025 | -76.0% |
| FY Dec 2024 | -102.3% |
| FY Dec 2023 | -161.7% |
| FY Dec 2022 | -135.6% |
| FY Dec 2021 | -129.3% |
| Jun 2026 | -113.1% |
| Mar 2026 | -104.2% |
| Dec 2025 | -76.0% |
| Sep 2025 | -156.9% |
| Jun 2025 | -207.2% |
| Mar 2025 | +121.8% |
| Dec 2024 | -102.3% |
| Sep 2024 | -26.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-50.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets XFOR
| FY Dec 2025 | -36.3% |
| FY Dec 2024 | -25.5% |
| FY Dec 2023 | -66.8% |
| FY Dec 2022 | -68.8% |
| FY Dec 2021 | -73.9% |
| Jun 2026 | -50.3% |
| Mar 2026 | -49.8% |
| Dec 2025 | -36.3% |
| Sep 2025 | -55.7% |
| Jun 2025 | -64.6% |
| Mar 2025 | +12.1% |
| Dec 2024 | -25.5% |
| Sep 2024 | -9.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital XFOR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | -22.9% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-55.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed XFOR
| FY Dec 2025 | -45.9% |
| FY Dec 2024 | -30.6% |
| FY Dec 2023 | -83.5% |
| FY Dec 2022 | -74.1% |
| FY Dec 2021 | -79.5% |
| Jun 2026 | -55.6% |
| Mar 2026 | -55.8% |
| Dec 2025 | -45.9% |
| Sep 2025 | -68.5% |
| Jun 2025 | -80.2% |
| Mar 2025 | -8.9% |
| Dec 2024 | -30.6% |
| Sep 2024 | -17.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
162.50x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing XFOR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 233.50x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | 3.23x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$202.1M
market value at close 2026-10-26 on 2026-07-31 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
Enterprise value XFOR
| FY Dec 2025 | $207.7M |
| FY Dec 2024 | $3.8B |
| FY Dec 2023 | $4.2B |
| FY Dec 2022 | $2.0B |
| FY Dec 2021 | $1.6B |
| Jun 2026 | $320.4M |
| Mar 2026 | $233.6M |
| Dec 2025 | $207.7M |
| Sep 2025 | $44.4M |
| Jun 2025 | $46.8M |
| Mar 2025 | $1.3B |
| Dec 2024 | $3.8B |
| Sep 2024 | $3.4B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-26.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield XFOR
| FY Dec 2025 | -24.5% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -3.7% |
| FY Dec 2021 | -4.2% |
| Jun 2026 | -19.0% |
| Mar 2026 | -24.7% |
| Dec 2025 | -24.5% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing XFOR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $35.1M | $2.6M | $0 | $0 |
| Operating income | -$86.9M | -$36.4M | -$107.5M | -$87.6M |
| Net income | -$79.2M | -$37.5M | -$101.2M | -$93.9M |
| EPS (diluted) | -1.87 | -5.59 | -17.07 | -1.52 |
| Operating cash flow | -$85.6M | -$130.9M | -$96.5M | -$77.1M |
| Cash | $217.0M | $55.7M | $99.2M | $121.7M |
| Long-term debt | $75.0M | $75.0M | $54.6M | $32.3M |
| Buybacks | n/a | n/a | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-27
XFOR Stock Sonar score 6/7 axes
Find similar shapesCompareXFOR ranks highest on growth (97th percentile) and institutional and government (50th), and lowest on risk and compliance (38th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
XFOR filings, in plain words
Are X4 Pharmaceuticals insiders buying or selling XFOR?
In the 180 days to 2026-10-27, X4 Pharmaceuticals insiders were net sellers, a net $451.0K: $11.9K of purchases and $462.9K of sales reported on Form 4, by 1 buyer and 3 sellers.
Are there planned insider sales of XFOR?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $361.7K of stock; the latest, by David Kirske, was filed 2026-10-01.
Read the full summary
In the 180 days to 2026-10-27, X4 Pharmaceuticals insiders were net sellers of XFOR, a net $451.0K across purchases and sales reported on Form 4 by 1 buyer and 3 sellers. Sales outweighed purchases more than tenfold by value. None of the 5 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $361.7K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
